Alnylam Pharmaceuticals
Alnylam Pharmaceuticals raises $360M Convertible Note at $25B valuation
Alnylam Pharmaceuticals: Convertible Note Funding Round
Alnylam Pharmaceuticals has successfully raised $360M in Convertible Note funding, reaching a valuation of $25B.
Company Overview
RNAi therapeutics
Funding Details
The Convertible Note round was led by Millennium Partners, with participation from Polaris Partners, Temasek Holdings.
Company Information
- Headquarters: 675 West Kendall Street, Cambridge, MA 02142
- Founded: 2002
- Employees: 2000+
- Category: Biotech
Investment
Alnylam Pharmaceuticals plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Millennium Partners: Verified investor in Convertible Note
- Polaris Partners: Verified investor in Convertible Note
- Temasek Holdings: Verified investor in Convertible Note
Company Info
Investors (3)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free